Episode Details

Wegovy’s explosive growth is rewriting Novo Nordisk’s story: prescriptions hit a million in just four weeks, not eleven — and 80% of users are new to GLP-1 drugs, proving it’s expanding the market. Despite a stock slump, Q2 adjusted numbers soared, fueling a higher full-year forecast. International wins — UAE dominance, European approvals, and a U.S. high-dose launch — signal global momentum. The CEO’s optimism hinges on whether this surge sustains through the year and drives real international revenue.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/30edb24b2ffed069